Developing Brain-Penetrant MYC/MYCN Degraders for Lethal Paediatric Brain Tumours

This project aims to develop new targeted therapies for lethal paediatric brain tumours, including diffuse intrinsic pontine glioma (DIPG) and medulloblastoma, which are driven by aberrant MYC/MYCN signalling and have very poor survival rates.

We will use a first-in-class, brain-penetrant MYC/MYCN degrader to uncover tumour-specific vulnerabilities through CRISPR-Cas9 functional genomics and identify effective drug combinations using systematic screening of clinically relevant compounds. Next-generation MYC degraders will be optimised for potency, selectivity, and brain penetration through medicinal chemistry. Lead compounds and rational combination therapies will then be validated in orthotopic and patient-derived brain tumour models.

This work will establish a strong preclinical foundation for translating MYC-targeted therapies toward future clinical trials for children with currently incurable brain cancers.

Eligibility

Domestic, International, PhD and Masters candidates

How to apply

Express your interest in this project by emailing A/Prof Belamy Cheung bcheung@ccia.unsw.edu.au . Include a copy of your CV and your academic transcript(s).

Further information on how to apply and scholarship deadlines can be found here HDR Application Process